Literature DB >> 34462900

Echocardiographic assessment of cardiac amyloidosis.

Tanushree Agrawal1, Sherif F Nagueh2.   

Abstract

Cardiac amyloidosis, a form of infiltrative cardiomyopathy, is associated with poor prognosis in untreated patients. Early diagnosis is important for timely initiation of effective therapies. Despite advances in diagnostic modalities, it remains a challenging diagnosis, requiring high index of clinical suspicion. Echocardiography represents the first-line cardiac imaging modality for evaluation of heart failure and suspected cardiac amyloidosis. In this review, we discuss echocardiographic findings in cardiac amyloidosis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac amyloidosis; Echocardiography; Heart failure; Restrictive cardiomyopathy

Mesh:

Year:  2021        PMID: 34462900     DOI: 10.1007/s10741-021-10165-y

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.654


  53 in total

1.  High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.

Authors:  V Sanchorawala; D G Wright; D C Seldin; R H Falk; K T Finn; L M Dember; J L Berk; K Quillen; J J Anderson; R L Comenzo; M Skinner
Journal:  Bone Marrow Transplant       Date:  2004-02       Impact factor: 5.483

2.  Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis.

Authors:  Jean D Sipe; Merrill D Benson; Joel N Buxbaum; Shu-ichi Ikeda; Giampaolo Merlini; Maria J M Saraiva; Per Westermark
Journal:  Amyloid       Date:  2014-09-29       Impact factor: 7.141

3.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

Authors:  S W Dubrey; K Cha; J Anderson; B Chamarthi; J Reisinger; M Skinner; R H Falk
Journal:  QJM       Date:  1998-02

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

5.  Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge.

Authors:  Bertil Ladefoged; Anne Dybro; Jonas Agerlund Povlsen; Henrik Vase; Tor Skibsted Clemmensen; Steen Hvitfeldt Poulsen
Journal:  Int J Cardiol       Date:  2020-01-25       Impact factor: 4.164

6.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Authors:  David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

7.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Authors:  Merrill D Benson; Márcia Waddington-Cruz; John L Berk; Michael Polydefkis; Peter J Dyck; Annabel K Wang; Violaine Planté-Bordeneuve; Fabio A Barroso; Giampaolo Merlini; Laura Obici; Morton Scheinberg; Thomas H Brannagan; William J Litchy; Carol Whelan; Brian M Drachman; David Adams; Stephen B Heitner; Isabel Conceição; Hartmut H Schmidt; Giuseppe Vita; Josep M Campistol; Josep Gamez; Peter D Gorevic; Edward Gane; Amil M Shah; Scott D Solomon; Brett P Monia; Steven G Hughes; T Jesse Kwoh; Bradley W McEvoy; Shiangtung W Jung; Brenda F Baker; Elizabeth J Ackermann; Morie A Gertz; Teresa Coelho
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

8.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Authors:  Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia
Journal:  Eur Heart J       Date:  2015-07-28       Impact factor: 29.983

9.  Clinical significance of histopathologic patterns of cardiac amyloidosis.

Authors:  T J Smith; R A Kyle; J T Lie
Journal:  Mayo Clin Proc       Date:  1984-08       Impact factor: 7.616

10.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Authors:  Mathew S Maurer; Jeffrey H Schwartz; Balarama Gundapaneni; Perry M Elliott; Giampaolo Merlini; Marcia Waddington-Cruz; Arnt V Kristen; Martha Grogan; Ronald Witteles; Thibaud Damy; Brian M Drachman; Sanjiv J Shah; Mazen Hanna; Daniel P Judge; Alexandra I Barsdorf; Peter Huber; Terrell A Patterson; Steven Riley; Jennifer Schumacher; Michelle Stewart; Marla B Sultan; Claudio Rapezzi
Journal:  N Engl J Med       Date:  2018-08-27       Impact factor: 91.245

View more
  2 in total

Review 1.  It Takes a Village: Multimodality Imaging of Cardiac Amyloidosis.

Authors:  Jean Michel Saad; Ahmed Ibrahim Ahmed; Dixitha Anugula; Yushui Han; Moath Said Alfawara; Mouaz H Al-Mallah
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

Review 2.  Multimodal Imaging and Biomarkers in Cardiac Amyloidosis.

Authors:  Mi-Hyang Jung; Suyon Chang; Eun Ji Han; Jong-Chan Youn
Journal:  Diagnostics (Basel)       Date:  2022-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.